Company intelligence / Profile preview

Enzyvant

Cary, North Carolina, United Statesdrug-dev.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Enzyvant has achieved FDA approval for RETHYMIC®, an allogeneic processed thymus tissue therapy for congenital athymia—a life-threatening pediatric immunodeficiency. The company continues to advance additional candidates targeting rare diseases in immunology and cardiopulmonology. Clinical trials include the evaluation of rodatristat ethyl for pulmonary arterial hypertension with a focus on addressing root causes rather than symptoms. The company merged with Altavant Sciences in December 2022 to expand its rare disease portfolio.

Therapeutic areas: Rare DiseasesCardiovascularImmunology
Modalities: Tissue-based regenerative therapies (e.g., allogeneic processed thymus tissue)Small molecules (e.g., rodatristat ethyl for pulmonary arterial hypertension)Enzyme replacement therapy (investigational)
Industry: Biotech

Drug pipeline

3 assets

Rethymic

Approved

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with academiaindustry partnersphysician associationsadvocacy groupsgovernment agenciesmanufacturing partnership with parent companies for new facility development

Beyond the preview

Go deeper on Enzyvant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzyvant.

Explore the full profile